Physician profile
Sam Alsabti
NPI 1639751837
$4,419.50
in general payments reported to CMS, 2019-2025
18 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $119 · 2024: $2,241 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205 · Travel and Lodging: $999 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.41 |
| Travel and Lodging | $999.46 |
| Education | $214.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Circulation INC | $1,236.46 | 2024 | Downstream Cartridge, Therox Ds2 Console, Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $619.45 | 2024-2025 | Lifevest |
| Boston Scientific Corporation | $454.12 | 2024-2025 | Avvigo Guidance System, Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Cardiva Medical, INC. | $274.40 | 2024-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Stryker Corporation | $252.79 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Clottriever Bold Catheter |
| Astrazeneca Pharmaceuticals LP | $225.79 | 2024-2025 | |
| Abiomed | $200.50 | 2024-2025 | Impella |
| Abbott Laboratories | $193.81 | 2024-2025 | Optis, Coroflow |
| Shockwave Medical, INC | $182.15 | 2025 | |
| Kestra Medical Technology Services, INC. | $181.44 | 2024-2025 | Assure Wcd |
| Penumbra, INC. | $142.91 | 2025 | Indigo System |
| Lilly USA, LLC | $119.25 | 2023 | Mounjaro |
| Chiesi USA, INC. | $99.09 | 2024 | Kengreal |
| Bridgebio Pharma, INC. | $82.09 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $76.59 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haemonetics Corporation | $36.24 | 2025 | Teg6s Hemostasis System |
| Novartis Pharmaceuticals Corporation | $24.07 | 2024 | |
| Teleflex LLC | $18.35 | 2025 | Trapliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Alsabti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.